

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI BIOLOGICS (CAYMAN) INC.

藥明生物技術有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2269)

**(1) GRANT OF RESTRICTED SHARES
UNDER RESTRICTED SHARE AWARD SCHEME; AND
(2) GRANT OF RESTRICTED SHARES UNDER SHARE AWARD
SCHEME FOR GLOBAL PARTNER PROGRAM**

**GRANT OF RESTRICTED SHARES UNDER RESTRICTED SHARE
AWARD SCHEME**

Reference is made to the announcements of WuXi Biologics (Cayman) Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) dated January 15, 2018 and January 18, 2018 (the “**RSA Announcements**”) in relation to the adoption of restricted share award scheme (the “**Restricted Share Award Scheme**”) and appointment of trustee (the “**RSA Trustee**”), a summary of the principal terms of which was set out in the RSA Announcements. Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as defined in the RSA Announcements.

The Board is pleased to announce that on November 28, 2022 (the “**Grant Date**”), it has approved the grant of 7,330,996 restricted shares (the “**RSA Restricted Shares**”) in aggregate to 681 employees of the Group (collectively, the “**RSA Grantees**”) (the “**RSA Grant**”), subject to acceptance of the RSA Grantee, pursuant to the Restricted Share Award Scheme. Details of the RSA Grant are set out as follows:

Number of Grant Shares:	an aggregate of 7,330,996 RSA Restricted Shares (the “ RSA Grant Shares ”), representing approximately 0.17% of the issued share capital of the Company as at the date of this announcement
-------------------------	--

Number of Grantees:	681 employees of the Group, and to the best knowledge of the Directors, none of the RSA Grantees is a Director, chief executive or substantial shareholder of the Company, or an associate (as defined under the Listing Rules) of any of them
Grant Date:	November 28, 2022
Market Price of the Shares:	The closing price of the Shares on the Grant Date as quoted on the Stock Exchange is HK\$47.35 per Share. The average closing price of the Shares for the five consecutive trading days immediately preceding the Grant Date as quoted on the Stock Exchange is HK\$48.88 per Share

The Company will issue and allot to the RSA Trustee 7,330,996 new Shares under the general mandate granted by the shareholders of the Company on June 10, 2022 and in accordance with the terms of the rules of the Restricted Share Award Scheme. The new Shares so issued will be held on trust for the RSA Grantees until the end of each vesting period which may differ among the RSA Grantees and be transferred to the RSA Grantees upon satisfaction of the relevant vesting conditions as may be specified by the Board at the time of making the RSA Grant.

The new Shares to be issued and allotted by the Company to the RSA Trustee represent approximately 0.17% of the Company's issued share capital as at the date of this announcement and approximately 0.17% of the Company's enlarged issued share capital after the issue and allotment. To the best of the Directors' knowledge, the RSA Trustee and its ultimate beneficial owners and all of the RSA Grantees are third parties independent of the Company and are not connected persons of the Company, and none of them is a director or a substantial shareholder of the Group (as defined under the Listing Rules) as at the time of granting the RSA Grant Shares.

The new Shares, when issued and fully paid, will rank *pari passu* among themselves and with the other Shares in issue, with the right to receive all dividends and other distributions declared, made or paid on or after the date of issue and allotment. Pursuant to the Restricted Share Award Scheme, the RSA Trustee shall not exercise the voting rights in respect of any Shares held by it under trust. Application will be made by the Company to the Listing Committee of the Stock Exchange for the grant of approval for the listing of, and permission to deal in, the 7,330,996 new Shares to be issued and allotted.

Taking into account the purposes and objectives of the Restricted Share Award Scheme, the Company considers that the RSA Grant is fair and reasonable, and is in the interests of the Company and its shareholders as a whole.

GRANT OF RESTRICTED SHARES UNDER SHARE AWARD SCHEME FOR GLOBAL PARTNER PROGRAM

Reference is made to the announcement of the Company dated June 16, 2021 (the “**GPP Announcement**”) in relation to the adoption of share award scheme for global partner program (the “**Global Partner Program Share Scheme**”) and appointment of trustee (“**GPP Trustee**”), a summary of the principal terms of which was set out in the GPP Announcement. Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as defined in the GPP Announcement.

The Board is pleased to announce that on November 28, 2022, it has approved the grant of 6,769,146 restricted shares (the “**GPP Restricted Shares**”) in aggregate to 234 employees of the Group (collectively, the “**GPP Grantees**”) (the “**GPP Grant**”), subject to acceptance of the GPP Grantee, pursuant to the Global Partner Program Share Scheme. Details of the GPP Grant are set out as follows:

Number of Grant Shares: an aggregate of 6,769,146 GPP Restricted Shares (the “**GPP Grant Shares**”), representing approximately 0.16% of the issued share capital of the Company as at the date of this announcement

Number of Grantees: 234 employees of the Group, and to the best knowledge of the Directors, none of the GPP Grantees is a Director, chief executive or substantial shareholder of the Company, or an associate (as defined under the Listing Rules) of any of them

Grant Date: November 28, 2022

Market Price of the Shares: The closing price of the Shares on the Grant Date as quoted on the Stock Exchange is HK\$47.35 per Share. The average closing price of the Shares for the five consecutive trading days immediately preceding the Grant Date as quoted on the Stock Exchange is HK\$48.88 per Share

The Company will issue and allot to the GPP Trustee 6,769,146 new Shares under the general mandate granted by the shareholders of the Company on June 10, 2022 and in accordance with the terms of the rules of the Global Partner Program Share Scheme. The new Shares so issued will be held on trust for the GPP Grantees until the end of each vesting period and be transferred to the GPP Grantees upon satisfaction of the relevant vesting conditions as may be specified by the Board at the time of making the GPP Grant.

The new Shares to be issued and allotted by the Company to the GPP Trustee represent approximately 0.16% of the Company's issued share capital as at the date of this announcement and approximately 0.16% of the Company's enlarged issued share capital after the issue and allotment. To the best of the Directors' knowledge, the GPP Trustee and its ultimate beneficial owners and all of the GPP Grantees are third parties independent of the Company and are not connected persons of the Company, and none of them is a director or a substantial shareholder of the Group (as defined under the Listing Rules) as at the time of granting the GPP Grant Shares.

The new Shares, when issued and fully paid, will rank *pari passu* among themselves and with the other Shares in issue, with the right to receive all dividends and other distributions declared, made or paid on or after the date of issue and allotment. Pursuant to the Global Partner Program Share Scheme, the GPP Trustee shall not exercise the voting rights in respect of any Shares held by it under trust. Application will be made by the Company to the Listing Committee of the Stock Exchange for the grant of approval for the listing of, and permission to deal in, the 6,769,146 new Shares to be issued and allotted.

Taking into account the purposes and objectives of the Global Partner Program Share Scheme, the Company considers that the GPP Grant is fair and reasonable, and is in the interests of the Company and its shareholders as a whole.

By order of the Board
WuXi Biologics (Cayman) Inc.
Dr. Ge Li
Chairman

Hong Kong, November 28, 2022

As at the date of this announcement, the Board comprises Dr. Zhisheng Chen and Dr. Weichang Zhou as executive Directors; Dr. Ge Li, Dr. Ning Zhao, Mr. Yibing Wu and Mr. Yanling Cao as non-executive Directors; and Mr. William Robert Keller and Mr. Kenneth Walton Hitchner III as independent non-executive Directors.

* *For identification purpose only*